Advanced systemic therapies in the treatment of moderate to severe atopic dermatitis - historical notes
| Date | Note |
|---|---|
| 05/10/2022 | Added tralokinumab, upadacitinib and abrocitinib approved at ERFC March, May, July 2022 |
| 24/03/2022 | Listing Dupilumab formulations by brand name rather than the generic description. |
| 15/12/2021 | East Region Formulary content agreed. |